Burney Co/ 13F: New $4.7M Stake in Insmed (INSM)

Burney Co/ disclosed a new position in Insmed Incorporated (NasdaqGS: INSM) in a filing on October 15, 2026. The firm acquired 41,026 shares valued at about $4.68 million. This new buy may indicate growing interest in the biotechnology sector, particularly in companies focused on rare and serious diseases.

What Changed in Burney Co/'s Insmed Position

Burney Co/ has opened a new position in Insmed, purchasing 41,026 shares. This acquisition marks the firm's initial stake in the company, showing a significant investment in Insmed's future potential.

Other Institutional Activity in Insmed

Several other institutional investors have also positioned themselves in Insmed. FMR, LLC grew its holdings by 2,983,411 shares, bringing its total to 16,143,583 shares worth about $1.55 billion. Meanwhile, BlackRock Inc. reduced its stake by 870,623 shares, ending with 15,807,984 shares valued at approximately $1.52 billion. JPMorgan Chase & Co. significantly cut its position by 13,722,293 shares, now holding 10,428,170 shares valued at around $1.00 billion.

Insmed Incorporated Stock Down 3.0%

As of October 16, 2026, Insmed shares recently traded around $96.20, which is below both their 50-day moving average of about $119.60 and their 200-day moving average of around $129.48. The stock is also more than 54% below its 52-week high of $212.75, indicating a challenging environment for the company despite its strong pipeline and potential.

Recent Earnings

Insmed reported trailing twelve-month revenue of approximately $1.14 billion, with a year-over-year revenue growth of 296.1%. However, the company has not been profitable, reporting a net margin of -76.9%. Insmed's next earnings report is scheduled for October 29, 2026, which could provide more insight into its financial performance and future outlook.

Insider Buying and Selling at Insmed Incorporated

In recent months, several insiders have sold shares of Insmed. For instance, Chief Operating Officer Roger Adsett sold 239,850 shares for about $31.96 million on August 10, 2026. Additionally, other insiders, including Martina Flammer and Melvin A. Sharoky, have also disposed of shares, indicating ongoing adjustments among the company's top executives.

Analysts Set New Price Targets

Analysts have had mixed views on Insmed lately. On October 12, 2026, Wolfe Research downgraded the stock to Peer Perform. In contrast, HC Wainwright reiterated its Buy rating with a target price of $220. Meanwhile, JP Morgan maintains an Overweight rating with a target of $175, reflecting the potential for recovery despite recent challenges.

About Insmed Incorporated

Insmed Incorporated specializes in developing therapies for patients with rare diseases. The company is known for its drug ARIKAYCE, designed for treating serious lung infections. Insmed is currently conducting a phase 3 clinical trial for another treatment, showing its commitment to innovation in the healthcare space.

Bottom Line

Investors will be watching closely for Insmed's upcoming earnings report on October 29, 2026, to gauge its performance and future direction. Burney Co/'s new position highlights the ongoing interest in biotech, but the stock's recent struggles indicate challenges ahead. Keep in mind that 13F filings are backward-looking: they show holdings as of the end of the reporting quarter and may not represent the fund's current position.